Summary Oncology Venture ApS (Oncology Venture), a subsidiary of Oncology Venture Sweden AB, is a developer of oncology products.The company offers products in the therapeutic areas of metastatic breast cancer, ovarian cancer, renal cancer, liver cancer, prostate cancer, multiple myeloma, and others.
It provides gene-tumor-technology for identifying patients with resistance to anticancer drug.Oncology Venture’s activities include in-licensing drugs with low response rate performing phase II trials on a selected population and identifying the ones that are positive for its proprietary biomarker; and out-licensing the drugs with high response rate.
It conducts research and development to discover new drugs.The company partners with other pharmaceutical companies to co-develop oncology drugs.
Oncology Venture is headquartered in Hoersholm, Denmark.
Oncology Venture ApS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 18.104.22.168) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 22.214.171.124) - Drugs in Development, 2021 Summary According to the recently published report ’TGF Beta Receptor Type 2 - Drugs in Development, 2021’; TGF Beta Receptor Type 2 (Transforming Growth Factor Beta...
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 126.96.36.199) - Drugs in Development, 2021 Summary According to the recently published report ’SerineThreonine Protein Kinase Pim 2 - Drugs in Development, 2021’; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto...
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 188.8.131.52) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 184.108.40.206) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
The global generic oncology drugs market exhibited strong growth during 2015-2020. Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the...
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
263 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
527 pages •
By Global Industry Analysts
• Apr 2021
- The Practice of Oncology Remains the Worst Affected by COVID-19. The Grim Scenario Sends Demand for Radiation Therapy Equipment Slumping by -4.8%
- The global market for Radiation Therapy Equipment is expected to decline by -4.8% in the year 2020 and thereafter recover to reach US$6.9 billion by the year...
Diagnostic Imaging Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.